hgen_home_2.png

The Cytokine Storm Company

Humanigen, Inc.

Recent Publications

The Lancet Respiratory Medicine – Peer-Review:

Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial

Journal of Medical Economics: Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective

About Us

We are a clinical stage biopharmaceutical company, developing our immunology and immuno-oncology portfolio of monoclonal antibodies. We are focusing our efforts on the development of our lead product candidate, lenzilumab, our proprietary Humaneered® (“Humaneered”) anti-human granulocyte-macrophage colony-stimulating factor (“GM-CSF”) monoclonal antibody.

AdobeStock_203971424.jpeg

"The more original a discovery the more obvious it seems afterwards."

Arthur Koestler